The small molecule GMX1778 is a potent inhibitor of NAD+ biosynthesis: strategy for enhanced therapy in nicotinic acid phosphoribosyltransferase 1-deficient tumors.
about
Nitrile-containing pharmaceuticals: efficacious roles of the nitrile pharmacophoreNew strategies to maximize therapeutic opportunities for NAMPT inhibitors in oncologyStructural and biochemical analyses of the catalysis and potency impact of inhibitor phosphoribosylation by human nicotinamide phosphoribosyltransferaseOrganization of GC/MS and LC/MS metabolomics data into chemical librariesExtracellular nicotinamide phosphoribosyltransferase, a new cancer metabokineSirtuin deacylases: a molecular link between metabolism and immunityMetabolomics analysis of metabolic effects of nicotinamide phosphoribosyltransferase (NAMPT) inhibition on human cancer cellsStructural basis for resistance to diverse classes of NAMPT inhibitorsNAMPT and NAPRT1: novel polymorphisms and distribution of variants between normal tissues and tumor samples.A rise in NAD precursor nicotinamide mononucleotide (NMN) after injury promotes axon degenerationPathways and subcellular compartmentation of NAD biosynthesis in human cells: from entry of extracellular precursors to mitochondrial NAD generation.Nicotinamide phosphoribosyl transferase (Nampt) is required for de novo lipogenesis in tumor cells.Target enzyme mutations are the molecular basis for resistance towards pharmacological inhibition of nicotinamide phosphoribosyltransferase.The Lkb1 metabolic sensor maintains haematopoietic stem cell survival.Depletion of the central metabolite NAD leads to oncosis-mediated cell death.Overcoming temozolomide resistance in glioblastoma via dual inhibition of NAD+ biosynthesis and base excision repairNext-generation NAMPT inhibitors identified by sequential high-throughput phenotypic chemical and functional genomic screens.Secretion of one adipokine Nampt/Visfatin suppresses the inflammatory stress-induced NF-κB activity and affects Nampt-dependent cell viability in Huh-7 cells.NAD(+) Metabolism and the Control of Energy Homeostasis: A Balancing Act between Mitochondria and the NucleusInhibition of Nicotinamide Phosphoribosyltransferase (NAMPT), an Enzyme Essential for NAD+ Biosynthesis, Leads to Altered Carbohydrate Metabolism in Cancer Cells.Inhibition of nicotinamide phosphoribosyltransferase (NAMPT) activity by small molecule GMX1778 regulates reactive oxygen species (ROS)-mediated cytotoxicity in a p53- and nicotinic acid phosphoribosyltransferase1 (NAPRT1)-dependent manner.Metabolic Response to NAD Depletion across Cell Lines Is Highly VariableSynthetic lethality of PARP and NAMPT inhibition in triple-negative breast cancer cellsExtreme Vulnerability of IDH1 Mutant Cancers to NAD+ Depletion.Pharmacological inhibition of nicotinamide phosphoribosyltransferase (NAMPT), an enzyme essential for NAD+ biosynthesis, in human cancer cells: metabolic basis and potential clinical implications.Extensive regulation of nicotinate phosphoribosyltransferase (NAPRT) expression in human tissues and tumors.Recycling nicotinamide. The transition-state structure of human nicotinamide phosphoribosyltransferase.Metabolomic signatures in lipid-loaded HepaRGs reveal pathways involved in steatotic progressionIntracellular NAD⁺ depletion enhances bortezomib-induced anti-myeloma activity.CD73 protein as a source of extracellular precursors for sustained NAD+ biosynthesis in FK866-treated tumor cellsMyc-Driven Glycolysis Is a Therapeutic Target in Glioblastoma.Dependence of tumor cell lines and patient-derived tumors on the NAD salvage pathway renders them sensitive to NAMPT inhibition with GNE-618Supplementation of nicotinic acid with NAMPT inhibitors results in loss of in vivo efficacy in NAPRT1-deficient tumor models.Targeting DNA polymerase ß for therapeutic intervention.A pancreatic ductal adenocarcinoma subpopulation is sensitive to FK866, an inhibitor of NAMPT.PBEF/NAMPT/visfatin: a promising drug target for treating rheumatoid arthritis?Radionuclide therapy via SSTR: future aspects from experimental animal studies.Metabolomics as a key integrator for "omic" advancement of personalized medicine and future therapies.The human NAD metabolome: Functions, metabolism and compartmentalization.Crystal structure-based comparison of two NAMPT inhibitors.
P2860
Q24569706-E1EA97DB-5A61-4F46-8BC5-4013B715852BQ26745678-401F2F45-1FBA-49AE-97AF-F14FB877F71CQ27690154-DC1B3B0E-0050-4A83-90AF-7FCC8D425DB2Q27702050-25D35D2B-771F-4536-9AB3-29BFFC48DFA0Q28069876-A211556E-C405-4A6D-968C-6B433E334472Q28283588-CCCE7CC2-C569-4F03-92DA-6686307F34E4Q28542558-62B35744-01CF-44FA-8999-107DE61C206CQ28543568-833EE706-8B4F-4E54-80B5-A0AB691FD112Q30366556-C45643CB-B13F-4636-897F-883B8C402F02Q30638030-D28D7AA3-0E42-4A92-9B51-70CCCC216ECCQ34179395-7600CE54-895F-496A-A32C-27E4B7AA224BQ34328772-9951C2EF-4C6F-4686-8530-D8A3EA253538Q34482044-C93618FA-47E5-437B-A1C5-BB836115EF00Q34568200-6F8050BC-A24D-455C-BBC8-B25F1CA424C0Q34737798-12AA4318-B944-4D57-B0C8-1FD7312A82AEQ34802264-B50FD89F-AB94-4E63-97E2-052040FD1C7FQ35030829-211330D9-9367-40E9-B07C-3A7BC251A782Q35169732-5F038C31-E9B9-4D97-ABA9-CF7A1C740D2DQ35805959-EDFE3813-F5D5-4854-A178-5D9C3404DCFAQ35860727-CED8086E-F714-4D92-9279-BB0A27A2DFCCQ36052583-83617A85-DB88-4130-AD1A-6FC23B84444FQ36155272-02460990-9100-472B-956D-64490DA96036Q36379543-88D58281-F3E4-4286-B6D3-60F4DA3FC13FQ36385589-3F6FE91D-F2F5-4009-B482-743DDCD54F22Q36579595-76AD3C39-D147-4A2C-9EB0-C2EB0807E4F1Q36739012-55F0E8AD-8C87-420A-97CF-6CBDC7DF64CDQ36768767-6B95CD5E-6273-4598-907D-EA2C05BF8A0AQ36947359-8356285D-C9AA-4BFC-9485-B55971ADA92FQ37098847-EFB98E55-1565-4857-82E9-D8A2D5828C1BQ37151029-8EEC147B-1673-4924-ACFC-6025FFCBF6DDQ37230411-3E0D987F-FE68-4F56-9075-AA162B7FB2DFQ37285546-AADC914D-4A3C-467B-815E-9F2018FA5A9FQ37448050-08AB5807-9CE5-450B-AB8A-74E0A3956F3FQ37489149-346EACEF-8E19-46DA-ADA0-FAEEE20082D9Q37619827-6A306266-39A9-4F6B-993F-4AD7847A67E5Q38005192-F0A72CA3-984B-4DCE-84EA-2FC2BBC493C6Q38008839-CD54FFE3-76F8-4C81-AE7A-E895E4A32D82Q38017698-3017CA5A-55C1-4ABA-9A07-1723531C1427Q38402636-2D5FFA6E-BFA9-4C01-87CD-FD5EECEF8DAFQ38635017-3909D1F1-D055-46E4-A42A-4A568B9877C5
P2860
The small molecule GMX1778 is a potent inhibitor of NAD+ biosynthesis: strategy for enhanced therapy in nicotinic acid phosphoribosyltransferase 1-deficient tumors.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 24 August 2009
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
The small molecule GMX1778 is ...... ransferase 1-deficient tumors.
@en
The small molecule GMX1778 is ...... ransferase 1-deficient tumors.
@nl
type
label
The small molecule GMX1778 is ...... ransferase 1-deficient tumors.
@en
The small molecule GMX1778 is ...... ransferase 1-deficient tumors.
@nl
prefLabel
The small molecule GMX1778 is ...... ransferase 1-deficient tumors.
@en
The small molecule GMX1778 is ...... ransferase 1-deficient tumors.
@nl
P2093
P2860
P356
P1476
The small molecule GMX1778 is ...... ransferase 1-deficient tumors.
@en
P2093
Abdelkrim Khadir
Alvin Berger
Anne Roulston
Cynthia Bernier
Daniel Goulet
Denis Paquette
Dominique Bédard
Elizabeth Koch
Emilie Turcotte
P2860
P304
P356
10.1128/MCB.00112-09
P407
P577
2009-08-24T00:00:00Z